• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

N Engl J Med . Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

tetano

Editor, Senior Moderator
N Engl J Med


. 2020 Jun 29.
doi: 10.1056/NEJMoa2021680. Online ahead of print.
Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

Leora R Feldstein[SUP] 1 [/SUP], Erica B Rose[SUP] 1 [/SUP], Steven M Horwitz[SUP] 1 [/SUP], Jennifer P Collins[SUP] 1 [/SUP], Margaret M Newhams[SUP] 1 [/SUP], Mary Beth F Son[SUP] 1 [/SUP], Jane W Newburger[SUP] 1 [/SUP], Lawrence C Kleinman[SUP] 1 [/SUP], Sabrina M Heidemann[SUP] 1 [/SUP], Amarilis A Martin[SUP] 1 [/SUP], Aalok R Singh[SUP] 1 [/SUP], Simon Li[SUP] 1 [/SUP], Keiko M Tarquinio[SUP] 1 [/SUP], Preeti Jaggi[SUP] 1 [/SUP], Matthew E Oster[SUP] 1 [/SUP], Sheemon P Zackai[SUP] 1 [/SUP], Jennifer Gillen[SUP] 1 [/SUP], Adam J Ratner[SUP] 1 [/SUP], Rowan F Walsh[SUP] 1 [/SUP], Julie C Fitzgerald[SUP] 1 [/SUP], Michael A Keenaghan[SUP] 1 [/SUP], Hussam Alharash[SUP] 1 [/SUP], Sule Doymaz[SUP] 1 [/SUP], Katharine N Clouser[SUP] 1 [/SUP], John S Giuliano Jr[SUP] 1 [/SUP], Anjali Gupta[SUP] 1 [/SUP], Robert M Parker[SUP] 1 [/SUP], Aline B Maddux[SUP] 1 [/SUP], Vinod Havalad[SUP] 1 [/SUP], Stacy Ramsingh[SUP] 1 [/SUP], Hulya Bukulmez[SUP] 1 [/SUP], Tamara T Bradford[SUP] 1 [/SUP], Lincoln S Smith[SUP] 1 [/SUP], Mark W Tenforde[SUP] 1 [/SUP], Christopher L Carroll[SUP] 1 [/SUP], Becky J Riggs[SUP] 1 [/SUP], Shira J Gertz[SUP] 1 [/SUP], Ariel Daube[SUP] 1 [/SUP], Amanda Lansell[SUP] 1 [/SUP], Alvaro Coronado Munoz[SUP] 1 [/SUP], Charlotte V Hobbs[SUP] 1 [/SUP], Kimberly L Marohn[SUP] 1 [/SUP], Natasha B Halasa[SUP] 1 [/SUP], Manish M Patel[SUP] 1 [/SUP], Adrienne G Randolph[SUP] 1 [/SUP]


AffiliationsExpand

Abstract

Background: Understanding the epidemiology and clinical course of multisystem inflammatory syndrome in children (MIS-C) and its temporal association with coronavirus disease 2019 (Covid-19) is important, given the clinical and public health implications of the syndrome.
Methods: We conducted targeted surveillance for MIS-C from March 15 to May 20, 2020, in pediatric health centers across the United States. The case definition included six criteria: serious illness leading to hospitalization, an age of less than 21 years, fever that lasted for at least 24 hours, laboratory evidence of inflammation, multisystem organ involvement, and evidence of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on reverse-transcriptase polymerase chain reaction (RT-PCR), antibody testing, or exposure to persons with Covid-19 in the past month. Clinicians abstracted the data onto standardized forms.
Results: We report on 186 patients with MIS-C in 26 states. The median age was 8.3 years, 115 patients (62%) were male, 135 (73%) had previously been healthy, 131 (70%) were positive for SARS-CoV-2 by RT-PCR or antibody testing, and 164 (88%) were hospitalized after April 16, 2020. Organ-system involvement included the gastrointestinal system in 171 patients (92%), cardiovascular in 149 (80%), hematologic in 142 (76%), mucocutaneous in 137 (74%), and respiratory in 131 (70%). The median duration of hospitalization was 7 days (interquartile range, 4 to 10); 148 patients (80%) received intensive care, 37 (20%) received mechanical ventilation, 90 (48%) received vasoactive support, and 4 (2%) died. Coronary-artery aneurysms (z scores ≥2.5) were documented in 15 patients (8%), and Kawasaki's disease-like features were documented in 74 (40%). Most patients (171 [92%]) had elevations in at least four biomarkers indicating inflammation. The use of immunomodulating therapies was common: intravenous immune globulin was used in 144 (77%), glucocorticoids in 91 (49%), and interleukin-6 or 1RA inhibitors in 38 (20%).
Conclusions: Multisystem inflammatory syndrome in children associated with SARS-CoV-2 led to serious and life-threatening illness in previously healthy children and adolescents. (Funded by the Centers for Disease Control and Prevention.).
 
Back
Top Bottom